Mediators of Inflammation

Mediators of Inflammation / 2022 / Article
Special Issue

Inflammation and Regional Immune Balance in Autoimmune Disorders

View this Special Issue

Research Article | Open Access

Volume 2022 |Article ID 5782922 | https://doi.org/10.1155/2022/5782922

Fei Li, Dan Han, Bo Wang, Wentao Zhang, Yan Zhao, Jing Xu, Liesu Meng, Kuanhou Mou, Shemin Lu, Wenhua Zhu, Yan Zhou, "Topical Treatment of Colquhounia Root Relieves Skin Inflammation and Itch in Imiquimod-Induced Psoriasiform Dermatitis in Mice", Mediators of Inflammation, vol. 2022, Article ID 5782922, 15 pages, 2022. https://doi.org/10.1155/2022/5782922

Topical Treatment of Colquhounia Root Relieves Skin Inflammation and Itch in Imiquimod-Induced Psoriasiform Dermatitis in Mice

Academic Editor: Shushan Yan
Received18 Jun 2021
Revised15 Dec 2021
Accepted27 Dec 2021
Published11 Jan 2022

Abstract

Itch is one of the major clinical manifestations of psoriasis, which is closely related with neurogenic inflammation and difficult to control. Colquhounia Root (CR) is a Chinese herb exhibiting broad bioactivities on anti-inflammation. This study was designed to explore the antipsoriatic and anti-itch potential of CR and its underlying mechanisms. Mice in a model of imiquimod-induced psoriasiform dermatitis were treated topically with CR for 7 days, and the severity of skin lesions and itch was significantly ameliorated. CR reduced the inflammatory cell infiltration, as well as mast cells in skins. Particularly, the expression of inflammatory cytokines and chemokine including Il17a, Il22, and Ccl20 and itch-related molecules such as SP, CGRP, and NGF in lesions were decreased in diseased mice upon application with CR. The normal human epidermal keratinocytes were stimulated with the M5 cytokine cocktail, the mixture of IL-17A, IL-22, Oncostatin M, IL-1α, and TNF-α, and cell viability and mRNA expression levels of inflammatory factors and itch-related molecules were measured after being treated with CR. We found that CR inhibited both cell hyperproliferation and overexpression of inflammatory cytokines and itch-related molecules in vitro. Altogether, we conclude that CR relieves psoriatic lesions and itch via controlling immunological and neurogenic inflammation.

1. Introduction

Psoriasis is a chronic immune-mediated inflammatory disease mainly manifested as scaly erythema and patches in the skin. Patients suffering from psoriasis often complain of disgusting appearance, chronic itch, and joint pain [13]. Itch is one of the most troublesome symptoms of psoriasis, affecting the quality of life and sleep of patients. It is probably unrelated to the severity of psoriasis due to its particular mechanisms [4].

The pathophysiological mechanism of itch in psoriasis, which is mainly related to mental stress and neurogenic inflammation, remains poorly understood. Studies have shown that itch-related molecules released by epidermal keratinocytes and other cells in the dermis such as calcitonin gene-related peptide (CGRP), substance P (SP), nerve growth factor (NGF), and TRPV1 and inflammatory cytokines (IL-17 and IL-22), as well as chemokine CCL20, are important in mechanisms of itch [510]. Their expressions are significantly increased in the skin specimens of psoriasis patients, involved in the occurrence and development of psoriatic itch [2, 11].

In the last few decades, considerable progress has been made in the treatment of psoriasis including topical or oral traditional medications, novel biologics, and phototherapies. With the in-depth study of psoriasis, psoriatic itch has gradually been noticed. However, traditional antipruritic therapies (such as antihistamines) are limited in the treatment of itch in psoriasis. Traditional topical drugs like vitamin D3 derivatives and coal tar for clinical treatment of psoriasis have little effect on itch or even aggravate it [12]. Biological agents, such as TNF-α and IL-17 inhibitors, can quickly and effectively relieve itch, but some patients could not afford them because of high prices or high-risk adverse reactions [13], such as infection, urticaria, and tumor in the long term [14]. Therefore, successful treatment of psoriatic itch is still challenging. It is necessary to further explore and develop treatment strategies and drugs to relieve psoriatic itch.

Nowadays, the use of botanical therapeutics has been taken attention by dermatologists, such as Tripterygium wilfordii and Colquhounia Root (CR) [15]. CR is a traditional Chinese medicine, containing several bioactive ingredients such as triptolide and tripterine [16], is widely used in the treatment of autoimmune-related diseases such as systemic lupus erythematosus, rheumatoid arthritis, chronic nephritis, vasculitis, and psoriasis, with anti-inflammatory and analgesic effects [1719]. However, it has not been reported whether CR has the effect of inhibiting itch in psoriasis. Therefore, we aim to explore the effects and mechanisms of topical treatment with CR.

2. Materials and Methods

2.1. Mice

Forty-one female C57BL/6J mice, weighing 18-20 g, were purchased from Xi’an Jiaotong University Laboratory Animal Center and were kept at a standardized breeding environment. Standard diet and water were available to all mice anytime. All animal experiments were approved by the Institutional Animal Ethics Committee of Xi’an Jiaotong University.

2.2. Preparation of CR

CR tablets (Z20027411) were provided by Pharmaceutical Factory of the Chongqing Academy of Chinese Mataria Medica. We grounded 5 g CR tablets into powder and then mixed it in 250 g Vaseline to keep the effective concentration which was 0.002%, and then stored it at 4°C.

2.3. Imiquimod- (IMQ-) Induced Psoriasiform Dermatitis (PsD) in Mice and Treatment

Mice were randomly divided into three groups, the normal control group, disease group (IMQ), and CR treated group (IMQ+CR). We followed the methods of William et al. to establish the IMQ-induced psoriasiform dermatitis mouse model [20]. Mice were anesthetized with isoflurane, and their hair on the back skin was shaved (). Then, 62.5 mg of IMQ creams (Mingxin Pharmaceutical Co., Ltd., Sichuan, China) was applied daily onto the dorsal skins for 7 consecutive days to induce psoriasiform dermatitis in the IMQ group and IMQ+CR group mice. CR were daily administered to the dorsal skins for 9 consecutive days from two days before IMQ application. Mice in the normal group were treated with Vaseline. A blinded observer measured the thickness of the dorsal skins by a vernier caliper daily and observed and photographed the back skin with a dermoscope simultaneously. Psoriasis Severity Index (PSI) scores were used to evaluate the severity of skin lesions every day [21], which were graded from 0 to 4 for erythema, thickness, scaling, and total. All mice were euthanized, and their skin specimens were stored for determination and further experiments. The experiment scheme is shown in Figure 1(a). Liver and renal injury biomarkers were carried out by an autoanalyzer (LABOSPECT 008 ASi, Hitachi, Japan).

2.4. Behavioral Tests

We did the behavioral tests following the methods of Sakai et al. [22]. Firstly, we pretreated and habituated all mice to a transparent acrylic box for 30 min twice. Twenty hours after each topical application, we videotaped the number of scratch bouts of mice for 30 minutes. Then, the scratch bouts of mice in videos were counted by a blinded observer. A scratch bout was defined as once or more times rapidly front and backward pointing and touching movement with hind claws in the skin lesions and ending by licking or biting the toes or placing the back claws on the floor. Other movements away from the treated area as ear scratching and grooming were excluded.

2.5. Histopathology and Immunohistochemistry (IHC)

Skin specimens in paraformaldehyde-fixed (4%) were embedded in paraffin for haematoxylin and eosin staining (H&E) and IHC. Mast cells were stained by Toluidine blue following the way of Puebla-Osorio et al. [23]. We assessed the histopathological alterations with computer-assisted quantitative image analysis in lesions, including epidermal thickness, area of Munro’s microabscesses (MM), and the number of mast cells. Tissue sections were prepared for IHC with SP (Cat, No. sc-21715, 1 : 50, Santa Cruze), CGRP (Cat, No. sc-57053, 1 : 50, Santa Cruze), and NGF (Cat, No. sc-32300, 1 : 50, Santa Cruze) antibodies. The integrated optical density (IOD) of SP, CGRP, and NGF in the image was measured by Image Pro plus 6 software.

2.6. mRNA Quantification

RNA, extracted from skin specimens with TRIzol reagent (Thermo Fisher Scientific) according to the instruction, was converted into cDNA with the RevertAid First Strand cDNA Synthesis kit (Thermo Fisher Scientific). Quantitative real-time polymerase chain reaction (qPCR) was performed on a PCR machine (CFX CNNNECT Real-time system; Bio Rad, Hercules, CA, USA). The gene-specific primers are summarized in Table 1. The data were analyzed with the 2ΔΔCT method and normalized by GAPDH.


Gene symbolSequence

Il17aF: 5-TTTTCAGCAAGGAATGTGGA-3
R: 5-TTCATTGTGGAGGGCAGAC-3
Il22F: 5-ATGAGTTTTTCCCTTATGGGGAC-3
R: 5-GCTGGAGTTGGACACCTCAA-3
Ccl20F: 5-GCCTCTCGTACATACAGACGC-3
R: 5-CCAGTTCTGCTTTGGATCAGG-3
SpF: 5-AAGCGGGATGCTGATTCCTC-3
R: 5-TCTTTCGTAGTTCTGCATTGCG-3
CgrpF: 5-GAGGGCTCTAGCTTGGACAG-3
R: 5-AAGGTGTGAAACTTGTTGAGGT-3
NgfF: 5-TGATCGGCGTACAGGCAGA-3
R: 5-GCTGAAGTTTAGTCCAGTGGG-3
GapdhF: 5-AGGTCGGTGTGAACGGATTTG-3
R: 5-TGTAGACCATGTAGTTGAGGTCA-3
IL6F: 5-CCAAGAGGTGAGTGCTTCCC-3
R: 5-CTGTTGTTCAGACTCTCTCCCT-3
CXCL8F: 5-CAAGGCTGGTCCATGCTCC-3
R: 5-TGCTATCACTTCCTTTCTGTTGC-3
IL1βF: 5-GCAACTGTTCCTGAACTCAACT-3
R: 5-ATCTTTTGGGGTCCGTCAACT-3
CCL20F: 5-CTGCTACTCCACCTCTGCG-3
R: 5-TTGCGCACACAGACAACTTT-3
SPF: 5-TGATCTGAATTACTGGTCCGACT-3
R: 5-TCCGGCAGTTCCTCCTTGA-3
CGRPF: 5-ATGCAGCACCATTCAGGTCTG-3
R: 5-CCAGCCGATGAGTCACACAG-3
NGFF: 5-GGCAGACCCGCAACATTACT-3
R: 5-CACCACCGACCTCGAAGTC-3
GAPDHF: 5-CTGGGCTACACTGAGCACC-3
R: 5-AAGTGGTCGTTGAGGGCAATG-3

2.7. Flow Cytometry

Skin samples from each group were cut into pieces using ophthalmic scissors and digested using collagenases (2.6 mg/ml, Sigma) and DNase (0.1 mg/ml, Sigma) for 1.5 h. The cell suspension was filtered by a 40 μm nylon net. Then, cells from the skin were stained with anti-mouse-BV785-CD45.2 (Cat, No. 109839, 1 : 200, BioLegend), anti-mouse-AF700-TCRβ (Cat, No. 109224, 1 : 200, BioLegend), anti-mouse-PE-Cy5-CD4 (Cat, No. 100514, 1 : 200, BioLegend), anti-mouse-BV711-CD8 (Cat, No. 100759, 1 : 200, BioLegend), anti-mouse-APC-CD11b (Cat, No. 101212, 1 : 200, BioLegend), anti-mouse-FITC-F4/80 (Cat, No. 123108, 1 : 200, BioLegend), anti-mouse-Pacific blue-Ly6G (Cat, No. 127612, 1 : 200, BioLegend), and anti-mouse-PE-γδT (Cat, No. 553178, 1 : 200, Becton Dickinson). Finally, we detected and analyzed all samples with a flow cytometer. Gating strategy of cells in flow cytometry is shown in supplementary Figure 1.

2.8. Cell Culture and Treatment

We performed all culture experiments on the normal human epidermal keratinocytes (NHEKs) which were obtained from ATCC (Manassas, VA). Cells were cultured with Dulbecco’s modified Eagle’s medium (DMEM, Hyclone) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml of penicillin, and 100 μg/ml of streptomycin and were placed in an incubator at a 37°C humidified atmosphere with 5% CO2. NHEKs were treated with 10 ng/ml of M5 cocktail (IL-17A, IL-22, Oncostatin M, IL-1α, and TNF-α) [24], with or without CR dissolved in DMSO for 24 h.

2.9. Cell Viability Assay

We tested the effect of CR on the growth of NHEKs by CCK-8 assay following the methods of Ru et al. 2020 [25]. We seeded NHEKs onto 96-well plates at a density of 2000 cells per well. Then, the medium was replaced with fresh medium containing 10 ng/ml M5 and various concentrations (0, 0.25 μg/ml, 0.5 μg/ml, 1 μg/ml, and 2 μg/ml) of CR and medium containing 0.1% DMSO were used as the vehicle control after 24 h. After 24 h incubation, 10 μl of CCK8 solution (Cat. No. AR1160, Boster) was added to each well. Following 4 h incubation at 37°C, the absorbance of each well at 450 nm was determined.

2.10. Statistical Analysis

Results are expressed as the and were analyzed statistically using Graphpad Prism software. A -test was used to compare the differences between two groups. One-way ANOVA with a post hoc comparison (Tukey’s HSD) test was used to compare the differences in more than two groups. Statistical significance was defined as .

3. Results

3.1. Topical Treatment of CR Alleviates the Psoriasis-Like Lesions Induced by IMQ

The IMQ-induced PsD model is one of the best psoriatic mouse models with similar immunological alteration to human [26]. In order to understand the anti-inflammatory effects of CR, we applied CR to IMQ-induced mice. Topical treatment of CR has shown no obvious damage to liver and renal function of mice or even improved related index compared with the IMQ group (Supplementary figure 2).

The erythema, thickness, and scaling were observed after IMQ application (Figures 1(b) and 1(c)). The severity of these lesions was increased continuously with daily IMQ application (Figure 1(d)). By comparison, the severity of the skin lesions observed in the IMQ-induced PsD mice was reduced by the coadministration of CR (Figures 1(b) and 1(c)). In these mice, reduced scales, skin thickness, and cumulative scores were observed from day 5 to day 7 compared with mice in the model group (Figure 1(d)). However, the erythema of skin in the CR-treated group was not relieved (Figure 1(d)). Under the dermoscope, regularly distributed dotted vessels and scales were observed in the IMQ group, while they were diminished in the CR-treated group.

The sections of the IMQ-treated group showed the representative histopathological changes of psoriasis with hyperkeratosis, parakeratosis, and acanthosis, while these features were absent in normal mice (Figure 2(a)). However, CR treatment partially inhibited these characteristic changes in psoriatic lesions (Figure 2(a)). Statistical analysis also showed a significant decrease in the epidermal thickness in CR-treated mice (Figure 2(b)). In human psoriasis, neutrophils aggregation in the cornified layer known as MM, indicated that neutrophils may play an important role in disease pathogenesis [27]. IMQ-treated skins also showed MM formation (Figure 2(c)). MM in the model group were larger and more numerous than those observed in CR-treated mice (Figure 2(c)). The average area of total MM of each mouse was dramatically diminished in CR-treated mice vs. model mice () (Figure 2(d)).

Taken together, these results suggest that CR treatment could alleviate the severity of IMQ-induced PsD in mice. Therefore, it is necessary to study how this treatment exerts its therapeutic effect on psoriasis.

3.2. CR Treatment Improves the Immune Microenvironment of the Psoriatic Skins of Mice

The immune cell infiltration in mouse skins was then evaluated by flow cytometry. After administration of IMQ cream for 7 days, a significant increase of CD45+ cells ratio was observed in the IMQ group () compared with the normal group (Figure 3(a)). The ratio of neutrophils located in the skins was also increased after applying IMQ () (Figure 3(a)). CR treatment significantly decreased both CD45+ cells and neutrophils (). However, the ratio of macrophages and αβT cells in the skin showed no statistical differences between each group, whereas the proportion of CD4+ and CD8+αβT cells was increased in the IMQ model group and decreased in the CR treatment group (Figure 3(a)).

Th17-related cells play an important role in inducing dermal inflammation and epidermal hyperplasia in psoriasis [28], so we analyzed the expression levels of inflammatory cytokines and chemokines in the mouse skins. IMQ treatment significantly induced the expression of Il17a, Il22, and Ccl20 compared with the normal group, which showed the proinflammatory effect of IMQ by promoting the release of inflammatory factors. Moreover, a significant decrease in the levels of Il17a, Il22, and Ccl20 was observed after CR treatment (Figure 3(b)).

These results suggest that topical CR treatment is more likely to have a direct anti-inflammatory effect on IMQ-induced PsD in mice.

3.3. Topical CR Application Relieves Psoriatic Itch and Reduces Itch-Related Mediators of Skins

As the IMQ mouse model is widely used in itch research of psoriasis, we observed the CR’s effect on mice’s itch behavior [22]. The counts of spontaneous scratch bouts were gradually increased in IMQ-treated mice compared with the control group (Figure 4(a)). CR application significantly reduced the scratch bouts since day 2 to day 7 (Figure 4(a)) and also diminished mast cells in dermis (Figures 4(b) and 4(c)). Mast cells are found to play a role in the induction or aggravation of psoriatic itch in previous studies [29]. The number of mast cells in the IMQ group was significantly higher than that in the normal control group. The reduction of mast cells by CR treatment was consistent with the results of itch behavioral test (Figures 4(b) and 4(c)). Both results suggest that CR can alleviate itch in psoriatic mice.

The pathogenesis of itch in psoriasis is still not fully understood. Nowadays, it is reported to be closely related with neurogenic inflammation [2]. To determine how CR treatment regulated itch in the IMQ model, we measured mRNA expression of itch-related genes Sp, Cgrp, and Ngf by RT-qPCR in skins. Sp () and Cgrp () in the IMQ group were increased vs. those in the control group (Figure 5(a)). Of note, Sp () and Cgrp () in the CR group were both reduced compared with those in the IMQ group (Figure 5(a)). But there were no differences in mRNA levels of Ngf among the three groups () (Figure 5(a)). The same results were also confirmed from protein level by IHC. The Sp, Cgrp, and Ngf in the epidermis of psoriatic lesions were all increased markedly () with IMQ application compared with the normal group, which were reduced () after CR treatment (Figures 5(b) and 5(c)). Thus, it suggests that CR could negatively regulate itch-related molecules in PsD mice’s skin to control itch.

3.4. CR Downregulates M5-Induced Inflammatory Cytokines and Itch-Related Molecules in NHEKs

Hyperproliferative keratinocytes not only mediate inflammation but also influence itch during psoriasis [30]. Consequently, the effects of CR on keratinocytes were then investigated. The cell viability of NHEKs treated with CR was measured using CCK-8 assay. After NHEKs being treated with different concentrations of CR, no significant toxicity was observed. In contrast, 0.5, 1, and 2 μg/ml of CR could slightly promote cell viability () (Figure 6(a)). In M5 (10 ng/ml) induced inflammatory condition in vitro, the viability of NHEKs was significantly enhanced after 24 h () (Figure 6(a)). However, when we combined CR (0.5 or 2 μg/ml) with M5 to treat keratinocytes, the induced cell viability was inhibited (Figure 6(a)). In addition, the inflammatory cytokines and itch-related molecules were determined in NHEKs with M5 stimulation. We found that M5 (10 ng/ml) could significantly upregulate mRNA levels of IL-6, CXCL8, IL-1β, and CCL20 () (Figure 6(b)). The expression of NGF was also increased in the M5 group (), while SP and CGRP did not. Interestingly, CR treatment partially decreased expression of inflammatory cytokines IL-6, CXCL8, IL-1β, and CCL20 and itch-related molecules SP, CGRP, and NGF induced by M5 () (Figure 6(b)). In general, these results suggest that CR treatment could regulate keratinocytes viability and reduce inflammation and the expression of some itch mediators in a psoriatic cell model.

4. Discussion

Nowadays, most treatment protocols are targeted at the inflammatory response of psoriasis, only a few of them specifically for improving psoriasis itch. The main compositions of CR tablets were analyzed by HPLC as triptolide and epicatechin in Zhou et al.’s study in 2018 [16]. Oral administration of CR has also been successfully used in the treatment of psoriasis [19]. However, the mechanisms of topical treatment with CR in psoriasis are still unclear. Long-term oral CR always accompanies with liver, kidney, and reproductive systemic damage, so that topical preparations of CR could be a better choice preventing these side effects.

Itch is a subjective sensation, which could be quantified by observing the spontaneous behaviors of experimental animals. Rapid back-and-forth movements of the hind paw around skin lesions in mice can imitate patients’ scratching behaviors. Therefore, we apply this model in our research. The results showed that scales and thickness of skin were significantly reduced in CR-treated mice, consistent with previous studies of Tripterygium wilfordii [31]. However, the erythema in the CR group was not improved than that in the IMQ group. We speculate that it may be related to irritant contact dermatitis with external application by CR. Even so, the overall inflammation of the psoriatic lesions was greatly improved, and the number of scratches was significantly reduced in the CR group. These observations suggest that CR can relieve inflammation and pruritus in psoriasis.

Excessive inflammatory response in psoriasis has been confirmed to be related with itch [2]. Several studies reported that CD4+ T cells were crucial for initiating and maintaining the pathogenic process of psoriasis. The percentage of CD4+T cells was increased in the blood of psoriasis patients [32]. CD4+ T cells in skins consist of different helper T (Th) cells (Th1, Th2, Th9, Th17, Th22, and Treg cells) [33]. In psoriasis, keratinocytes regulate differentiation and activation of Th17 and Th22 cells by producing IL-1β and IL-6 [28]. In our study, the total ratio of αβT cells did not change significantly among three groups. However, the increased proportion of CD4+/CD8+αβT cells in the IMQ group was decreased by topical application of CR. The ratio of CD4+/CD8+αβT cells is positively related with Koebner phenomenon caused by scratching in psoriasis [34, 35]. Scratch-induced skin injury is definitely correlated with itch. Consistent with previous research, we observed an increase in neutrophil infiltration in IMQ-induced PsD in mice, as well as scratch behaviors [22, 27]. Previous studies have shown that scratch injury to epidermal keratinocytes promoted the release of CCL20 and CXCL8, which was related to the recruitment of both neutrophils and IL-17a-producing immune cells [36]. CCL20 was expressed abundantly in human psoriatic epidermis [9, 37]. Dupilumab inhibits the IL-4/IL-13 signaling pathway to reduce itching and itching in atopic dermatitis, which may reduce the release of CCL20 from keratinocytes and also reduce Th17 cell infiltration [38]. As well as in psoriasis, the enrichment of IL-17A-producing immune cells leads to produce high levels of IL-17A, which further stimulates keratinocytes producing CCL20, CXCL8, and IL-36γ to recruit more IL-17A-producing immune cells and neutrophils [39]. In our findings, the neutrophil infiltration and also increasing expression of CCL20 in IMQ treated mice were both inhibited by CR. As well in vitro, dexamethasone partially inhibited scratch-induced CXCL8 and CCL20 secretion in the keratinocyte model [36]. In order to mimic a psoriatic environment, we chose an M5-induced keratinocyte model to investigate the effects of CR. As expected, CR reduced the expression levels of inflammatory cytokines IL-6, IL-8, CXCL8, and CCL20. Interestingly, we observed that CR could promote cell viability slightly in NHEKs, while in NHEKs treated with M5, CR inhibited cell viability. We speculate that CR might regulate the viability of keratinocytes under different circumstances, which should be explored in further study.

Notably, the number of mast cells was significantly reduced in lesions of CR application. Several researches observed that mast cells are hyperactivated in psoriatic lesions of progressive stage. The use of certain medications to treat psoriasis, such as glucocorticosteroids, may lead a decline of the mast cell count [11]. Our observation indicates that CR may function as an inhibitor of itch in psoriasis by decreasing the number of mast cells in skin lesions.

In addition, the itch sensation is transmitted to the brain via itch neural pathways from skin lesions [40, 41]. Sensory nerve fibers increased in the psoriatic epidermis and dermal papilla, which were stimulated (endogenous or exogenous) by various neuropeptides and neurotrophic molecule, such as CGRP, SP, and NGF. Also, in the epidermis, neuropeptides released from the nerve fibers stimulate keratinocytes to release proinflammatory cytokines such as IL-6 and IL-8. On the other hand, CGRP and SP induce the release of vasoactive amine by mast cells, promoting the infiltration of neutrophils and T cells closely related with itch [4245]. The main source of NGF in the skin is keratinocytes [46]. The expression of NGF in psoriatic patients with pruritus is higher than that without pruritus [47]. These molecules work directly or indirectly on the nerve and lead to or aggravate the degree of itch in psoriasis [48, 49]. In our research, topical CR preparation can significantly relieve itch accompanied with reduced levels of CGRP, SP, and NGF in lesions from psoriatic mice. Additionally, in a psoriatic cell model, itch-related molecules SP, CGRP, and NGF were found decreased in NHEK cotreated with CR and M5. However, the expression of CGRP and SP in vitro was not upregulated by M5. We speculate that M5-induced keratinocytes may not be an optimal itching cell model in psoriasis.

5. Conclusion

In summary, we firstly prove that CR can not only inhibit the increased mast cells and neutrophils in lesions but also downregulate the inflammatory factors and neuropeptides and neurotrophic molecule to reduce the inflammation and itch in IMQ-induced murine model of psoriasis, which is also validated in a psoriatic cell model (Figure 7). In conclusion, CR is considered to be an ideal topical therapeutic drug for anti-itch treatment not just anti-inflammation in psoriasis.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare no commercial or financial conflict of interest.

Authors’ Contributions

Fei Li and Dan Han designed the study, performed the majority of the experiments, analyzed the data, and wrote the manuscript; Bo Wang, Wentao Zhang, Yan Zhao, and Jing Xu performed experiments and analyzed data; Liesu Meng and Shemin Lu provided expert technical assistance; Kuanhou Mou provided clinical advice and critical discussion of work; Wenhua Zhu and Yan Zhou designed the study, supervised the project, and wrote the manuscript.

Acknowledgments

This work is supported by the National Natural Science Foundation of China (81703130 and 82171724), Key Research and Development Program of Shaanxi Province of China (2020KW-047), and the Clinical Research Award of the First Affiliated Hospital of Xi’an Jiaotong University, China (XJTU1AF-CRF-2019-027 and 2021ZXY-12).

Supplementary Materials

Supplementary 1 Supplementary Figure 1: gating strategy of skin cells in flow cytometry. Supplementary 2 Supplementary Figure 2: effect of psoriatic inflammation and CR on liver and renal function of mice. (Supplementary Materials)

References

  1. J. C. Szepietowski and A. Reich, “Pruritus in psoriasis: an update,” European Journal of Pain, vol. 20, no. 1, pp. 41–46, 2016. View at: Publisher Site | Google Scholar
  2. E. Komiya, M. Tominaga, Y. Kamata, Y. Suga, and K. Takamori, “Molecular and cellular mechanisms of itch in psoriasis,” International Journal of Molecular Sciences, vol. 21, no. 21, p. 8406, 2020. View at: Publisher Site | Google Scholar
  3. G. Yosipovitch, A. Goon, J. Wee, Y. H. Chan, and C. L. Goh, “The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis,” The British Journal of Dermatology, vol. 143, no. 5, pp. 969–973, 2000. View at: Publisher Site | Google Scholar
  4. B. Elewski, A. F. Alexis, M. Lebwohl et al., “Itch: an under-recognized problem in psoriasis,” Journal of the European Academy of Dermatology and Venereology, vol. 33, no. 8, pp. 1465–1476, 2019. View at: Publisher Site | Google Scholar
  5. B. Amatya, H. el-Nour, M. Holst, E. Theodorsson, and K. Nordlind, “Expression of tachykinins and their receptors in plaque psoriasis with pruritus,” The British Journal of Dermatology, vol. 164, no. 5, pp. 1023–1029, 2011. View at: Publisher Site | Google Scholar
  6. R. Saraceno, C. E. Kleyn, G. Terenghi, and C. E. M. Griffiths, “The role of neuropeptides in psoriasis,” The British Journal of Dermatology, vol. 155, no. 5, pp. 876–882, 2006. View at: Publisher Site | Google Scholar
  7. J. Yamaguchi, M. Aihara, Y. Kobayashi, T. Kambara, and Z. Ikezawa, “Quantitative analysis of nerve growth factor (NGF) in the atopic dermatitis and psoriasis horny layer and effect of treatment on NGF in atopic dermatitis,” Journal of Dermatological Science, vol. 53, no. 1, pp. 48–54, 2009. View at: Publisher Site | Google Scholar
  8. F. Cevikbas, X. Wang, T. Akiyama et al., “A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1,” The Journal of Allergy and Clinical Immunology, vol. 133, no. 2, pp. 448–460.e7, 2014. View at: Publisher Site | Google Scholar
  9. J. Pène, S. Chevalier, L. Preisser et al., “Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes,” Journal of Immunology, vol. 180, no. 11, pp. 7423–7430, 2008. View at: Publisher Site | Google Scholar
  10. B. Strober, B. Sigurgeirsson, G. Popp et al., “Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials,” International Journal of Dermatology, vol. 55, no. 4, pp. 401–407, 2016. View at: Publisher Site | Google Scholar
  11. K. Jaworecka, J. Muda-Urban, M. Rzepko, and A. Reich, “Molecular aspects of pruritus pathogenesis in psoriasis,” International Journal of Molecular Sciences, vol. 22, no. 2, p. 858, 2021. View at: Publisher Site | Google Scholar
  12. A. W. Armstrong and C. Read, “Pathophysiology, clinical presentation, and treatment of psoriasis: a review,” JAMA, vol. 323, no. 19, pp. 1945–1960, 2020. View at: Publisher Site | Google Scholar
  13. G. Yosipovitch, J. Soung, J. Weiss et al., “Secukinumab provides rapid relief from itching and pain in patients with moderate-to-severe psoriasis: patient symptom diary data from two phase 3, randomized, placebo-controlled clinical trials,” Acta Dermato-Venereologica, vol. 99, no. 9, pp. 820-821, 2019. View at: Publisher Site | Google Scholar
  14. M. Kamata and Y. Tada, “Safety of biologics in psoriasis,” The Journal of Dermatology, vol. 45, no. 3, pp. 279–286, 2018. View at: Publisher Site | Google Scholar
  15. B. Farahnik, D. Sharma, J. Alban, and R. K. Sivamani, “Topical botanical agents for the treatment of psoriasis: a systematic review,” American Journal of Clinical Dermatology, vol. 18, no. 4, pp. 451–468, 2017. View at: Publisher Site | Google Scholar
  16. W. Zhou, G. Shi, J. Bai, S. Ma, Q. Liu, and X. Ma, “Colquhounia Root Tablet Protects Rat Pulmonary Microvascular Endothelial Cells against TNF--Induced Injury by Upregulating the Expression of Tight Junction Proteins Claudin-5 and ZO-1,” Evidence-based Complementary and Alternative Medicine, vol. 2018, Article ID 1024634, 11 pages, 2018. View at: Publisher Site | Google Scholar
  17. M. Jiang, H. Zhang, and Y. Ding, “Research progress on pharmacological activities and clinical applications of Tripterygium glycosides,” Chinese Archives of Traditional Chinese Medicine, vol. 39, no. 3, pp. 59–63, 2021. View at: Google Scholar
  18. X. L. Wu, J. B. Li, and S. L. Mo, “Clinical observation on colquhounia root tablet in treating lipid metabolism disturbance secondary to nephrotic syndrome,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 22, no. 1, pp. 30–32, 2002. View at: Google Scholar
  19. X. Han, H. Mou, and L. M. Wang, “Clinical effect analysis of colquhounia root tablet in the treatment of 46 cases of psoriasis vulgaris,” China Journal of Leprosy and Skin Diseases, vol. 6, pp. 588-589, 2004. View at: Google Scholar
  20. W. R. Swindell, K. A. Michaels, A. J. Sutter et al., “Imiquimod has strain-dependent effects in mice and does not uniquely model human psoriasis,” Genome Medicine, vol. 9, no. 1, p. 24, 2017. View at: Publisher Site | Google Scholar
  21. S. R. Feldman, D. M. Bushnell, P. A. Klekotka et al., “Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice,” The Journal of Dermatological Treatment, vol. 27, no. 3, pp. 224–227, 2016. View at: Publisher Site | Google Scholar
  22. K. Sakai, K. M. Sanders, M. R. Youssef et al., “Mouse model of imiquimod-induced psoriatic itch,” Pain, vol. 157, no. 11, pp. 2536–2543, 2016. View at: Publisher Site | Google Scholar
  23. N. Puebla-Osorio, S. N. E. Sarchio, S. E. Ullrich, and S. N. Byrne, “Detection of infiltrating mast cells using a modified toluidine blue staining,” Methods in Molecular Biology, vol. 1627, pp. 213–222, 2017. View at: Publisher Site | Google Scholar
  24. K. Guilloteau, I. Paris, N. Pedretti et al., “Skin inflammation induced by the synergistic action of IL-17A, IL-22, Oncostatin M, IL-1{alpha}, and TNF-{alpha} recapitulates some features of psoriasis,” Journal of Immunology, vol. 184, no. 9, pp. 5263–5270, 2010. View at: Publisher Site | Google Scholar
  25. Y. Ru, H. Li, R. Zhang et al., “Role of keratinocytes and immune cells in the anti-inflammatory effects of Tripterygium wilfordii Hook. f. in a murine model of psoriasis,” Phytomedicine, vol. 77, article 153299, 2020. View at: Publisher Site | Google Scholar
  26. K. Nakajima and S. Sano, “Mouse models of psoriasis and their relevance,” The Journal of Dermatology, vol. 45, no. 3, pp. 252–263, 2018. View at: Publisher Site | Google Scholar
  27. L. van der Fits, S. Mourits, J. S. A. Voerman et al., “Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis,” Journal of Immunology, vol. 182, no. 9, pp. 5836–5845, 2009. View at: Publisher Site | Google Scholar
  28. R. Yoshiki, K. Kabashima, T. Honda et al., “IL-23 from Langerhans Cells Is Required for the Development of Imiquimod- Induced Psoriasis-Like Dermatitis by Induction of IL-17A-Producing γδ T Cells,” The Journal of Investigative Dermatology, vol. 134, no. 7, pp. 1912–1921, 2014. View at: Publisher Site | Google Scholar
  29. K. Gupta and I. T. Harvima, “Mast cell-neural interactions contribute to pain and itch,” Immunological Reviews, vol. 282, no. 1, pp. 168–187, 2018. View at: Publisher Site | Google Scholar
  30. H. S. Kim and G. Yosipovitch, “The skin microbiota and itch: is there a link?” Journal of Clinical Medicine, vol. 9, no. 4, p. 1190, 2020. View at: Publisher Site | Google Scholar
  31. J. Zhao, T. di, Y. Wang et al., “Multi-glycoside of Tripterygium wilfordii Hook. f. ameliorates imiquimod-induced skin lesions through a STAT3-dependent mechanism involving the inhibition of Th17-mediated inflammatory responses,” International Journal of Molecular Medicine, vol. 38, no. 3, pp. 747–757, 2016. View at: Publisher Site | Google Scholar
  32. R. M. El-Gharabawy, A. S. Ahmed, and A. H. Al-Najjar, “Mechanism of action and effect of immune-modulating agents in the treatment of psoriasis,” Biomedicine & Pharmacotherapy, vol. 85, pp. 141–147, 2017. View at: Publisher Site | Google Scholar
  33. T. Nomura, K. Kabashima, and Y. Miyachi, “The panoply of αβT cells in the skin,” Journal of Dermatological Science, vol. 76, no. 1, pp. 3–9, 2014. View at: Publisher Site | Google Scholar
  34. E. Theodorakopoulou, Z. Z. N. Yiu, C. Bundy et al., “Early- and late-onset psoriasis: a cross-sectional clinical and immunocytochemical investigation,” The British Journal of Dermatology, vol. 175, no. 5, pp. 1038–1044, 2016. View at: Publisher Site | Google Scholar
  35. B. S. Baker, A. V. Powles, S. Lambert, H. Valdimarsson, and L. Fry, “A prospective study of the Koebner reaction and T lymphocytes in uninvolved psoriatic skin,” Acta Dermato-Venereologica, vol. 68, no. 5, pp. 430–434, 1988. View at: Google Scholar
  36. K. Furue, T. Ito, Y. Tanaka et al., “Cyto/chemokine profile of in vitro scratched keratinocyte model: implications of significant upregulation of CCL20, CXCL8 and IL36G in Koebner phenomenon,” Journal of Dermatological Science, vol. 94, no. 1, pp. 244–251, 2019. View at: Publisher Site | Google Scholar
  37. T. G. Kim, H. Jee, J. Fuentes-Duculan et al., “Dermal clusters of mature dendritic cells and T cells are associated with the CCL20/CCR6 chemokine system in chronic psoriasis,” The Journal of Investigative Dermatology, vol. 134, no. 5, pp. 1462–1465, 2014. View at: Publisher Site | Google Scholar
  38. E. L. Simpson, T. Bieber, E. Guttman-Yassky et al., “Two phase 3 trials of dupilumab versus placebo in atopic dermatitis,” The New England Journal of Medicine, vol. 375, no. 24, pp. 2335–2348, 2016. View at: Publisher Site | Google Scholar
  39. E. G. Harper, C. Guo, H. Rizzo et al., “Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis,” The Journal of Investigative Dermatology, vol. 129, no. 9, pp. 2175–2183, 2009. View at: Publisher Site | Google Scholar
  40. S. Bourane, B. Duan, S. C. Koch et al., “Gate control of mechanical itch by a subpopulation of spinal cord interneurons,” Science, vol. 350, no. 6260, pp. 550–554, 2015. View at: Publisher Site | Google Scholar
  41. M. Lay and X. Dong, “Neural mechanisms of itch,” Annual Review of Neuroscience, vol. 43, no. 1, pp. 187–205, 2020. View at: Publisher Site | Google Scholar
  42. A. Dallos, M. Kiss, H. Polyánka, A. Dobozy, L. Kemény, and S. Husz, “Effects of the neuropeptides substance P, calcitonin gene-related peptide, vasoactive intestinal polypeptide and galanin on the production of nerve growth factor and inflammatory cytokines in cultured human keratinocytes,” Neuropeptides, vol. 40, no. 4, pp. 251–263, 2006. View at: Publisher Site | Google Scholar
  43. G. J. Burbach, K. H. Kim, A. S. Zivony et al., “The neurosensory tachykinins substance P and neurokinin A directly induce keratinocyte nerve growth factor,” The Journal of Investigative Dermatology, vol. 117, no. 5, pp. 1075–1082, 2001. View at: Publisher Site | Google Scholar
  44. I. S. Song, N. W. Bunnett, J. E. Olerud et al., “Substance P induction of murine keratinocyte PAM 212 interleukin 1 production is mediated by the neurokinin 2 receptor (NK-2R),” Experimental Dermatology, vol. 9, no. 1, pp. 42–52, 2000. View at: Publisher Site | Google Scholar
  45. Y. M. Park and C. W. Kim, “The effects of substance P and vasoactive intestinal peptide on interleukin-6 synthesis in cultured human keratinocytes,” Journal of Dermatological Science, vol. 22, no. 1, pp. 17–23, 1999. View at: Publisher Site | Google Scholar
  46. C. Pincelli, “Nerve growth factor and keratinocytes: a role in psoriasis,” European Journal of Dermatology, vol. 10, no. 2, pp. 85–90, 2000. View at: Google Scholar
  47. M. Nakamura, M. Toyoda, and M. Morohashi, “Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors,” The British Journal of Dermatology, vol. 149, no. 4, pp. 718–730, 2003. View at: Publisher Site | Google Scholar
  48. K. Sakai, K. M. Sanders, M. R. Youssef et al., “Role of neurturin in spontaneous itch and increased nonpeptidergic intraepidermal fiber density in a mouse model of psoriasis,” Pain, vol. 158, no. 11, pp. 2196–2202, 2017. View at: Publisher Site | Google Scholar
  49. X. Kodji, K. L. Arkless, Z. Kee et al., “Sensory nerves mediate spontaneous behaviors in addition to inflammation in a murine model of psoriasis,” The FASEB Journal, vol. 33, no. 2, pp. 1578–1594, 2019. View at: Publisher Site | Google Scholar

Copyright © 2022 Fei Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views78
Downloads114
Citations

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.